Variable | Score Range | N | All Patients, n = 584 | JA-PASS+, n = 385 | JA-PASS−, n = 199 | JA-CASS+, n = 236 | JA-CASS−, n = 107 |
---|---|---|---|---|---|---|---|
Female, n (%) | 584 | 464 (79.5) | 303 (78.7) | 161 (80.9) | 180 (76.3) | 87 (81.3) | |
Onset age, yrs | 584 | 2.8 (1.7, 5.8) | 2.9 (1.8, 5.8) | 2.7 (1.7, 6) | 4.7 (2.5, 8) | 4.5 (1.8, 10.6) | |
Disease duration, yrs | 584 | 3.6 (1.3, 7.5) | 4.1 (1.9, 7.6) | 1.8 (0.5, 6.5) | 7.1 (4.1, 10.1) | 6.6 (3.9, 9.9) | |
Age at visit, yrs | 584 | 8.8 (4.8, 12.9) | 9.2 (5.4, 12.9) | 8.1 (3.4, 12.4) | 12.1 (9.7, 15.2) | 12.8 (10.1, 15.6) | |
ILAR category, n (%) | 584 | ||||||
Systemic arthritis | 43 (7.4) | 22 (5.7) | 21 (10.6) | 18 (7.6) | 10 (9.3) | ||
Oligoarthritis persistent | 258 (44.2) | 168 (43.6) | 90 (45.2) | 98 (41.5) | 41 (38.3) | ||
Oligoarthritis extended | 93 (15.9) | 66 (17.1) | 27 (13.6) | 39 (16.5) | 19 (17.8) | ||
Polyarthritis RF-negative | 132 (22.6) | 89 (23.1) | 43 (21.6) | 49 (20.8) | 21 (19.6) | ||
Polyarthritis RF-positive | 9 (1.5) | 7 (1.8) | 2 (1) | 5 (2.1) | 3 (2.8) | ||
Psoriatic arthritis | 13 (2.2) | 11 (2.9) | 2 (1) | 9 (3.8) | 1 (0.9) | ||
Enthesitis-related arthritis | 12 (2.1) | 6 (1.6) | 6 (3) | 9 (3.8) | 3 (2.8) | ||
Undifferentiated arthritis | 24 (4.1) | 16 (4.2) | 8 (4) | 9 (3.8) | 9 (8.4) | ||
Parent or child well-being VAS score | 0–10 | 569 | 1.5 (0, 5) | 0.5 (0, 2) | 5 (3, 6) | 0.5 (0, 1) | 3 (1, 5) |
Parent or child pain VAS score | 0–10 | 561 | 0.5 (0, 4) | 0 (0, 1.5) | 5 (2, 6.5) | 0 (0, 1) | 3.25 (0.5, 6) |
Parent or child disease activity VAS score | 0–10 | 561 | 1 (0, 4.5) | 0.5 (0, 1.5) | 5 (3, 7) | 0 (0, 1) | 3.25 (1, 6) |
Parent or child JAFS total score | 0–30 | 576 | 0 (0, 3) | 0 (0, 1) | 3 (1, 6) | 0 (0, 1) | 1 (0, 4) |
Parent or child PRQL total score | 0–30 | 559 | 3 (1, 6) | 2 (0, 4) | 7 (3, 11) | 2 (0, 4) | 5 (3, 8) |
Parent or child PRQL-PhH score | 0–15 | 563 | 2 (0, 4) | 1 (0, 3) | 4 (2, 7) | 1 (0, 2) | 3 (1.75, 5) |
Parent or child PRQL-PsH score | 0–15 | 559 | 1 (0, 3) | 1 (0, 2) | 2 (1, 4) | 1 (0, 2) | 1 (1, 3) |
Physician global assessment VAS | 0–10 | 478 | 0.5 (0, 4.5) | 0 (0, 4.5) | 5 (2.5, 4.5) | 0 (0, 4.5) | 3.5 (1, 4.5) |
No. disease-active joints | 0–73 | 478 | 1 (0, 2) | 0 (0, 1) | 3 (1, 5) | 0 (0, 1) | 2 (1, 4) |
No. swollen joints | 0–68 | 478 | 1 (0, 2) | 0 (0, 1) | 2 (1, 4) | 0 (0, 1) | 2 (1, 3) |
No. tender joints | 0–73 | 478 | 1 (0, 2) | 0 (0, 1) | 2 (1, 5) | 0 (0, 1) | 2 (1, 4) |
No. restricted joints | 0–71 | 478 | 1 (0, 2) | 0 (0, 1) | 2 (1, 4) | 0 (0, 1) | 1 (0, 3.75) |
ESR, mm/h | 20–140 | 390 | 16 (10, 29) | 13 (8, 29) | 31 (15, 29) | 13 (8, 29) | 24 (14, 29) |
C-reactive protein, mg/dl | < 0.46–infinity* | 400 | 0.3 (0.3, 0.6) | 0.3 (0.3, 0.6) | 0.6 (0.3, 0.6) | 0.3, (0.3, 0.6) | 0.3 (0.3, 0.6) |
↵* All values below 0.46 mg/dl were converted to 0.3 mg/dl. JA-PASS: parent acceptable symptom state in juvenile arthritis; JA-CASS: child acceptable symptom state in juvenile arthritis; ILAR: International League of Associations for Rheumatology; RF: rheumatoid factor; VAS: visual analog scale; JAFS: Juvenile Arthritis Functionality Scale; PRQL: Paediatric Rheumatology Quality of Life Scale; PhH: physical health; PsH: psychosocial health; ESR: erythrocyte sedimentation rate.